EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Transcriptome-based classification to predict FOLFIRINOX response in a real-world metastatic pancreatic cancer cohort

Marjolein F Lansbergen, Mark P G Dings, Paul Manoukian, Arantza Fariña, Cynthia Waasdorp, Gerrit K J Hooijer, Joanne Verheij, Jan Koster, Danny A Zwijnenburg, Johanna W Wilmink, Jan Paul Medema, Frederike Dijk und 2 weitere

Translational Research · 2024-11 · 273 · 137-147

DOI: 10.1016/j.trsl.2024.08.002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Translational Research, 2024-11. Verfasst von Marjolein F Lansbergen und 13 weiteren Autor:innen. Beteiligte Einrichtung: Amsterdam UMC, location University of Amsterdam, Center for Experimental and Molecular Medicine, Laboratory of Experimental Oncology and Radiobiology…. Hauptthemen laut MEDLINE: Leucovorin, Oxaliplatin, Irinotecan, Fluorouracil. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Horizon 2020 MSCA, Horizon 2020 Framework Programme, ZonMw.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic ductal adenocarcinoma (PDAC) is often diagnosed at metastatic stage and typically treated with fluorouracil, leucovorin, irinotecan and oxaliplatin (FOLFIRINOX). Few patients benefit from this treatment. Molecular subtypes are prognostic in particularly resectable PDAC and might predict treatment response. This study aims to correlate molecular subtypes in metastatic PDAC with FOLFIRINOX responses using real-world data, providing assistance in counselling patients. We collected 131 RNA-sequenced metastatic biopsies and applied a network-based meta-analysis using published PDAC classifiers. Subsequent survival analysis was performed using the most suitable classifier. For validation, we developed an immunohistochemistry (IHC) classifier using GATA6 and keratin-17 (KRT17), and applied it to 86 formalin-fixed paraffin-embedded samples of advanced PDAC. Lastly, GATA6 knockdown models were generated in PDAC organoids and cell lines. We showed that the PurIST classifier was the most suitable classifier. With this classifier, classical tumors had longer PFS and OS than basal-like tumors (PFS: 216 vs. 78 days, p = 0.0002; OS: 251 vs. 195 days, p = 0.049). The validation cohort showed a similar trend. Importantly, IHC GATA6low patients had significantly shorter survival with FOLFIRINOX (323 vs. 746 days, p = 0.006), but no difference in non-treated patients (61 vs. 54 days, p = 0.925). This suggests that GATA6 H-score predicts therapy response. GATA6 knockdown models did not lead to increased FOLFIRINOX responsiveness. These data suggest a predictive role for subtyping (transcriptomic and GATA6 IHC), though no direct causal relationship was found between GATA6 expression and chemoresistance. GATA6 immunohistochemistry should be seamlessly added to current diagnostics and integrated into upcoming clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LeucovorinOxaliplatinIrinotecanFluorouracilPancreatic NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsTranscriptomeGATA6 Transcription FactorHumansMaleFemaleMiddle AgedCohort StudiesAgedCell Line, TumorCarcinoma, Pancreatic DuctalNeoplasm MetastasisTreatment Outcome

Stichwörter der Autor:innen

Carcinoma, Pancreatic ductalDrug resistance, NeoplasmFOLFIRINOXGene expression profilingImmunohistochemistry

Substanzen

LeucovorinOxaliplatinIrinotecanFluorouracilfolfirinoxGATA6 Transcription FactorGATA6 protein, human

Autor:innen und Institutionen

  • Amsterdam UMC, location University of Amsterdam, Center for Experimental and Molecular Medicine, Laboratory of Experimental Oncology and Radiobiology, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands; Amsterdam UMC, l…
  • Amsterdam UMC, location University of Amsterdam, Center for Experimental and Molecular Medicine, Laboratory of Experimental Oncology and Radiobiology, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands; Cancer Center Am…
  • Cancer Center Amsterdam, Amsterdam, the Netherlands; Amsterdam UMC, location University of Amsterdam, Pathology, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands.
  • Amsterdam UMC, location University of Amsterdam, Medical Oncology, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam, the Netherlands.

Förderung

  • Horizon 2020 MSCA
  • Horizon 2020 Framework Programme
  • ZonMw

Zitieren

APA

Lansbergen, M. F., Dings, M. P. G., Manoukian, P., Fariña, A., Waasdorp, C., Hooijer, G. K. J., Verheij, J., Koster, J., Zwijnenburg, D. A., Wilmink, J. W., Medema, J. P., Dijk, F., van Laarhoven, H. W. M., & Bijlsma, M. F. (2024). Transcriptome-based classification to predict FOLFIRINOX response in a real-world metastatic pancreatic cancer cohort. Translational Research, 273, 137-147. https://doi.org/10.1016/j.trsl.2024.08.002

Vancouver

Lansbergen MF, Dings MPG, Manoukian P, Fariña A, Waasdorp C, Hooijer GKJ, et al. Transcriptome-based classification to predict FOLFIRINOX response in a real-world metastatic pancreatic cancer cohort. Translational Research. 2024;273:137-147. doi:10.1016/j.trsl.2024.08.002

BibTeX
@article{Lansbergen2024,
  author = {Lansbergen, Marjolein F and Dings, Mark P G and Manoukian, Paul and Fariña, Arantza and Waasdorp, Cynthia and Hooijer, Gerrit K J and Verheij, Joanne and Koster, Jan and Zwijnenburg, Danny A and Wilmink, Johanna W and Medema, Jan Paul and Dijk, Frederike and van Laarhoven, Hanneke W M and Bijlsma, Maarten F},
  title = {Transcriptome-based classification to predict FOLFIRINOX response in a real-world metastatic pancreatic cancer cohort},
  journal = {Translational Research},
  year = {2024},
  volume = {273},
  pages = {137--147},
  doi = {10.1016/j.trsl.2024.08.002}
}
Kostenlos starten →